Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Åndedrætsmekanik til levering af individualiseret eksogent overfladeaktivt stof (REMEDIES)

2. november 2026 opdateret af: Anna Lavizzari, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Et randomiseret kontrolleret forsøg med oscillerende mekanik versus iltningsbaserede kriterier for overfladeaktivt terapi

This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:

  1. to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
  2. to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.

Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.

Study Arms:

A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

458

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Milan, Italien
        • Rekruttering
        • Fondazione IRCCs Cà Granda Ospedale Maggiore Policlinico
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 måneder til 7 måneder (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Gestational age (GA) ≥ 27+0 and < 33+0 weeks
  2. Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥ 5.
  3. Inborn
  4. Written parental consent obtained
  5. Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care

Exclusion Criteria:

  1. Major congenital anomalies
  2. Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
  3. Surfactant therapy prior to the study entry
  4. Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
  5. Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations…)
  6. Any clinical condition which may place the infants at undue risk as deemed by clinicians
  7. Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
  8. Outborn patients

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: A/Control

Surfactant administration following clinical assessment

Surfactant is administered following oxygenation-based criteria

Eksperimentel: B/Intervention

Surfactant administration following both lung mechanics assessment and clinical assessment

Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Days of respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of required respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
First surfactant administration
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Time of first surfactant administration (in hours)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of non-invasive respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of non-invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of invasive respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients intubated and mechanically ventilated
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients intubated and mechanically ventilated

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients receiving multiple surfactant doses
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients receiving multiple surfactant doses

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days on supplemental oxygen
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days on supplemental oxygen

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Total cumulative oxygen exposure
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Total cumulative oxygen exposure computed as the time integral of the FiO2 values

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving more than 28 days of respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving more than 28 days of respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing BPD
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing BPD according to the definition by NICHD 2016

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing air-leaks
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing air-leaks

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing prematurity-associated complications
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing prematurity-associated complications (severe intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), sepsis, retinopathy of prematurity (ROP), patent ductus arteriosus requiring pharmacological or surgical treatment)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants discharged home with oxygen or respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants discharged home with oxygen or respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days to achieve full-enteral feeding
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days to achieve full-enteral feeding (160 ml/kg/day of milk intake)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of hospitalization
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of hospitalization

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving postnatal steroids
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving postnatal steroids

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. december 2023

Primær færdiggørelse (Anslået)

30. maj 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

9. december 2022

Først indsendt, der opfyldte QC-kriterier

28. marts 2023

Først opslået (Faktiske)

30. marts 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner